Brendan P. Eckelman - 13 Mar 2024 Form 4 Insider Report for Inhibrx, Inc.

Role
Chief Scientific Officer
Signature
/s/ Kelly D. Deck, as attorney in fact for Brendan P. Eckelman
Issuer symbol
N/A
Transactions as of
13 Mar 2024
Net transactions value
-$67,062
Form type
4
Filing time
15 Mar 2024, 16:48:29 UTC
Previous filing
12 Mar 2024
Next filing
24 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INBX Stock Option (right to buy) Options Exercise $67,062 -1,898 -17% $35.33 9,177 13 Mar 2024 Common Stock 1,898 $33.63 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Twenty-five percent (25%) of the total shares subject to the stock option became exercisable on January 15, 2022, with the balance to vest and become exercisable in equal successive monthly installments for thirty-six (36) months thereafter.